RxDoctor Payments Data

David Vega, APRN

Family · Reno, NVNPI 1821608266

Payments from drug & device makers

$1,122in general payments, 2019–2025

Across 47 payments — averaging $23.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$414
  • AbbVie$168
  • Lilly USA, LLC$115
  • Indivior Inc.$112
  • Amgen$74
  • Astellas Pharma US Inc$43
  • plus $195 from 10 others

What the payments were for

  • Food & beverage$1,122100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,122 in reported general payments places this provider in the 70th percentile of 1,501 family providers in Nevada.

See all family providers in Nevada

Medicare billing

Part B allowed, 2024
$5,180
Medicare patients
15
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin19$29,561
FarxigaDapagliflozin Propanediol15$12,526
TrulicityDulaglutide11$12,319
MyrbetriqMirabegron12$8,880
Tresiba Flextouch U-100Insulin Degludec12$5,920
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,746
Rosuvastatin Calcium43$998
Atorvastatin Calcium48$943
Pantoprazole Sodium23$730
Losartan Potassium52$712
Omeprazole37$549
Amlodipine Besylate44$440
Gabapentin44$430
Albuterol Sulfate HfaAlbuterol Sulfate19$406
Glipizide ErGlipizide35$367

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$20$29,56119 claims
AstraZenecaFarxiga$414$12,52615 claims
Lilly USA, LLCTrulicity$115$12,31911 claims
Astellas Pharma US IncMyrbetriq$43$8,88012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,501 family providers in Nevada.

Other family in Reno

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →